Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Status:
Active, not recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to
evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in
patients with Type I and Type II HAE.